Skip to content

Study · Non-randomized trial · n = 6 · 1992

4 results

The effect of vasoactive intestinal polypeptide on the lower esophageal sphincter in achalasia.

Guelrud M, Rossiter A, Souney PF, Rossiter G, Fanikos J, Mujica V

Gastroenterology1 Aug 1992Cited by 26 (Europe PMC)

PMID1634056 (opens in a new tab)DOI10.1016/0016-5085(92)90824-i (opens in a new tab)PepBankPUB-01634056
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In six patients with achalasia, intravenous VIP caused a dose-dependent decrease in lower esophageal sphincter pressure.

    In plain wordsIn six patients with achalasia, VIP lowered the pressure of the lower esophageal sphincter, more at higher doses.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseLES pressure in achalasia
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    1.5, 3 and 5 pmol.kg-1.min-1 · intravenousAs given in this study (human).

    Source sentences

    Summary
    In achalasia the three doses of VIP caused a dose-dependent decrease in LESP
    1 context sentence
    Summary · context
    LES pressure (LESP) and LES relaxation were compared in four healthy volunteers and in six patients with achalasia.
  2. 02HumanNon-randomized trialEfficacy outcome

    In six patients with achalasia, intravenous VIP significantly improved lower esophageal sphincter relaxation.

    In plain wordsIn six patients with achalasia, VIP improved relaxation of the lower esophageal sphincter.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseLES relaxation in achalasia
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    1.5, 3 and 5 pmol.kg-1.min-1 · intravenousAs given in this study (human).

    Source sentences

    Summary
    with a significant improvement in LES relaxation.
    1 context sentence
    Summary · context
    LES pressure (LESP) and LES relaxation were compared in four healthy volunteers and in six patients with achalasia.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with achalasia, VIP at 5 pmol.kg-1.min-1 produced a maximal decrease of 51% in lower esophageal sphincter pressure.

    In plain wordsIn patients with achalasia, the highest VIP dose lowered the pressure of the lower esophageal sphincter by up to 51%.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseMaximal LES pressure decrease at 5 pmol.kg-1.min-1
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    5 pmol.kg-1.min-1 · intravenousAs given in this study (human).

    Measurements

    Maximal LESP decrease
    51%
    5 pmol.kg-1.min-1 VIP, achalasia

    Source sentences

    Summary
    A dose of 5 pmol.kg-1.min-1 produced a maximal decrease of 51% in LESP.
    1 context sentence
    Summary · context
    LES pressure (LESP) and LES relaxation were compared in four healthy volunteers and in six patients with achalasia.
  4. 04HumanNon-randomized trialEfficacy outcome

    In four healthy volunteers, intravenous VIP at 3 and 5 pmol.kg-1.min-1 had no effect on esophageal motility, like placebo.

    In plain wordsIn four healthy volunteers, VIP did not change esophageal movement, as with placebo.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeEsophageal motility in healthy volunteers
    Study

    n = 4

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    3 and 5 pmol.kg-1.min-1 · intravenousAs given in this study (human).

    Source sentences

    Summary
    Neither placebo nor 3 and 5 pmol.kg-1.min-1 of VIP produced any effect on esophageal motility in healthy volunteers.
    1 context sentence
    Summary · context
    LES pressure (LESP) and LES relaxation were compared in four healthy volunteers and in six patients with achalasia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.